The cytotoxic efficacies of (I) decitabine ± talazoparib, (II) decitabine ± APE1 inhibitor III, and (III) talazoparib ± APE1 inhibitor III were analyzed in CD34+ MDS/CMML cells and in CD34+ or CD34− AML cells (Table 1, Figure 2). This evidence concerns the gene APEX1 and acute myeloid leukemia.